Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
EASL and mRECIST criteria differ from each other in terms of the number of target lesions (all versus < = 2) and calculation method (bidimensional versus unidimensional). Therefore, the investigators aimed to retrospectively analyze and compare the clinical outcomes among patients with hepatocellular carcinoma who were treated with different modalities of therapy according to the BCLC classification, and detect the possible predictors of post-treatment outcomes.
Background:
EASL and mRECIST criteria differ from each other in terms of the number of target lesions (all versus < = 2) and calculation method (bidimensional versus unidimensional). Therefore, the investigators aimed to retrospectively analyze and compare the clinical outcomes among patients with hepatocellular carcinoma (HCC) who were treated with different modalities of therapy according to the BCLC classification, and detect the possible predictors of post-treatment outcomes.
Methods:
This work was conducted at the departments of tropical medicine and gastroenterology, internal medicine, and general surgery. This study included patients that matched our eligibility criteria for a period of five years started from June 2015 to May 2020. The study purpose was to retrospectively analyze the clinical outcomes among patients with HCC who were treated with different modalities of therapy according to the BCLC classification, and detect the possible predictors of post-treatment favorable outcomes. The data of the patients were extracted and retrospectively reviewed from the patients' records and the databases of both hospitals (SUH and SOI).
During the period of recruitment, 407 patients diagnosed with HCC admitted to our departments and followed-up attending outpatient clinics, Sohag University Hospitals, over a 5 years period.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Favorable outcome | Cure or stable disease |
| |
| Unfavorable outcome | Progressive (deteriorate/Recurrence) or Death |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Radiofrequency ablation | Device | Radiofrequency ablation of the tumour |
|
| Measure | Description | Time Frame |
|---|---|---|
| CURE (Number of patients cured completely from the disease) | the HCC is treated (disappearance of all lesions) | one-year |
| STABLE Disease (Number of patients with neither progression nor cure from the disease) | NONE of the other outcomes' criteria | one-year |
| PROGRESSIVE((Number of patients with progression of the disease) (measured by follow-up CT scans, increase in size, appearance of new intratumoral lesions, or appearance of new lesions | increase in size - appearance of new intratumoral lesions - new lesions | one-year |
| Measure | Description | Time Frame |
|---|---|---|
| DEATH (Number of patients died from the disease) | Mortality rate | one-year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
This work was conducted at the departments of tropical medicine and gastroenterology, internal medicine, and general surgery. This study included patients that matched our eligibility criteria for a period of five years started from June 2015 to May 2020. The study purpose was to retrospectively analyze the clinical outcomes among patients with HCC who were treated with different modalities of therapy according to the BCLC classification, and detect the possible predictors of post-treatment favorable outcomes.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Emad A. Ahmed, MD, PhD | Sohag University | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
| Trance-arterial chemoembolization | Drug | Trance-arterial chemotherapy |
|
|
| Liver resection | Procedure | non-anatomical or anatomical liver resection |
|
| Combined radiofrequency ablation + percutaneous ethanol injection | Combination Product | combined therapy |
|
| Percutaneous ethanol injection | Drug | Percutaneous ethanol injection of HCC |
|
|
| Systemic chemotherapy | Drug | Systemic chemotherapy |
|
|
| Sorafenib | Drug | Sorafenib |
|
|
| Viscum | Dietary Supplement | Viscum for HCC |
|
| Symptomatic treatment | Drug | Symptomatic treatment |
|
|
| ID | Term |
|---|---|
| D006528 | Carcinoma, Hepatocellular |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008113 | Liver Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D004066 | Digestive System Diseases |
| D008107 | Liver Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000078703 | Radiofrequency Ablation |
| D006498 | Hepatectomy |
| D000431 | Ethanol |
| D020360 | Neoadjuvant Therapy |
| D000077157 | Sorafenib |
| D010166 | Palliative Care |
| ID | Term |
|---|---|
| D000078702 | Radiofrequency Therapy |
| D013812 | Therapeutics |
| D055011 | Ablation Techniques |
| D013514 | Surgical Procedures, Operative |
| D013505 | Digestive System Surgical Procedures |
| D000438 | Alcohols |
| D009930 | Organic Chemicals |
| D003131 | Combined Modality Therapy |
| D010671 | Phenylurea Compounds |
| D014508 | Urea |
| D000577 | Amides |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009536 | Niacinamide |
| D009539 | Nicotinic Acids |
| D000147 | Acids, Heterocyclic |
| D006571 | Heterocyclic Compounds |
| D011725 | Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D005791 | Patient Care |
| D006296 | Health Services |
| D005159 | Health Care Facilities Workforce and Services |
Not provided
Not provided